AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2013-01-10
Target enrollment:
Participant gender:
Summary
RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating
patients with advanced or metastatic solid tumors or refractory non-Hodgkin's lymphoma.